Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A phase 1/2 trial of Sacituzumab tirumotecan in ovarian cancer and non-small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting.
Overview
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) is a phase 1/2 interventional study registered as NCT04152499 by Klus Pharma Inc., with 1410 participants enrolled, started 2020-02-28 and due to reach its primary completion in 2026-12-31. Interventions recorded: SKB264. Conditions listed: Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Shares Sichuan Kelun-Biotech, Ovarian cancer.